To examine the relationship between HK-II expression and sorafenib sensitivity in patients with HCC, we analyzed the degree of HK-II immunopositivity in HCC patients who had been treated with sorafenib (Figure S3). Here, HK2 is linked to hepatocellular carcinoma.